logo-loader
viewAnixa Biosciences

Anixa Biosciences commercializing its Ccheck prostate cancer test, working on breast cancer vaccine

Anixa Biosciences, Inc. (NASDAQ: ANIX) CEO Dr Amit Kumar spoke with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The biotechnology company is focused on harnessing the body's immune system to fight cancer. It recently announced the commercial launch of its Cchek prostate cancer confirmation test.

Quick facts: Anixa Biosciences

Price: 3.38 USD

NASDAQ:ANIX
Market: NASDAQ
Market Cap: $70.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

16 hours, 56 minutes ago

2 min read